Invasive Candidiasis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Invasive candidiasis is an infection caused by a type of fungus called Candida is a serious infection that can affect the blood, heart, brain, eyes, bones, and other parts of the body. Candida species are frequent colonizers of the human alimentary tract and skin that have emerged as important nosocomial pathogens, in tandem with advances in modern medical therapeutics. Risk factors for invasive candidiasis include exposure to broad-spectrum antibiotics and cancer chemotherapy, advanced care of premature neonates, major abdominal surgery, organ transplantation, prolonged stay in an intensive care setting, implanted medical devices such as vascular catheters and prosthetic heart valves, and parenteral feeding. Recent treatment directives have been shaped by the widespread introduction of echinocandins, highly potent and safe antifungals, into clinical use, as well as important changes in drug susceptibility patterns and the emergence of known and novel drug-resistant Candida species. Advances in molecular diagnostics have the potential to guide the early targeted treatment of high-risk patients.

The global incidence of cases of Invasive candidiasis has been estimated between 550,000 to 825,00 cases annually, with an associated crude mortality rate varies between 22% to 43%.

 

The competitive landscape of Invasive Candidiasis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Invasive Candidiasis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Invasive Candidiasis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Invasive Candidiasis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          caspofungin acetate      Merck Sharp & Dohme Corp.     Phase 3

2          Anidulafungin    Pfizer    Phase 3

3          FK463  Astellas Pharma Inc      Phase 2

4          APX001            Amplyx Pharmaceuticals            Phase 2

5          Rezafungin       Cidara Therapeutics Inc.            Phase 3

6          Ibrexafungerp   Scynexis, Inc.   Phase 3

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033